Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Non-Current Deffered Revenue (2016 - 2018)

Corvus Pharmaceuticals' Non-Current Deffered Revenue history spans 4 years, with the latest figure at $869000.0 for Q4 2018.

  • Quarterly Non-Current Deffered Revenue fell 9.48% to $869000.0 in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $869000.0 through Dec 2018, down 9.48% year-over-year, with the annual reading at $869000.0 for FY2018, 9.48% down from the prior year.
  • Non-Current Deffered Revenue came in at $869000.0 for Q4 2018, up from $627000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $1.4 million in Q4 2016 to a low of $627000.0 in Q3 2018.
  • The 4-year median for Non-Current Deffered Revenue is $1.1 million (2017), against an average of $1.0 million.
  • Year-over-year, Non-Current Deffered Revenue skyrocketed 113.4% in 2016 and then crashed 41.02% in 2018.
  • Corvus Pharmaceuticals' Non-Current Deffered Revenue stood at $642000.0 in 2015, then skyrocketed by 113.4% to $1.4 million in 2016, then dropped by 29.93% to $960000.0 in 2017, then dropped by 9.48% to $869000.0 in 2018.
  • Per Business Quant, the three most recent readings for CRVS's Non-Current Deffered Revenue are $869000.0 (Q4 2018), $627000.0 (Q3 2018), and $738000.0 (Q2 2018).